Protagenic Therapeutics (OTCMKTS:PTIX) and WNS (NYSE:WNS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
94.9% of WNS shares are held by institutional investors. 41.0% of Protagenic Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Protagenic Therapeutics and WNS’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Protagenic Therapeutics||N/A||N/A||-$2.56 million||N/A||N/A|
|WNS||$809.10 million||3.85||$105.43 million||$2.25||27.54|
WNS has higher revenue and earnings than Protagenic Therapeutics.
Volatility & Risk
Protagenic Therapeutics has a beta of -7.31, indicating that its share price is 831% less volatile than the S&P 500. Comparatively, WNS has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Protagenic Therapeutics and WNS, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
WNS has a consensus target price of $69.60, suggesting a potential upside of 12.31%. Given WNS’s higher possible upside, analysts plainly believe WNS is more favorable than Protagenic Therapeutics.
This table compares Protagenic Therapeutics and WNS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
WNS beats Protagenic Therapeutics on 10 of the 11 factors compared between the two stocks.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
WNS (Holdings) Limited, a business process management company, together with its subsidiaries, provides data, voice, analytical, and business transformation services worldwide. It operates through two segments, WNS Global BPM and WNS Auto Claims BPM. The company offers industry-specific services to clients primarily in insurance; travel and leisure; diversified businesses, including manufacturing, retail, consumer packaged goods, media and entertainment, and telecommunication; utilities; consulting and professional services; healthcare; banking and financial services; and shipping and logistics industries. It also provides shared services, such as customer interaction, finance and accounting, research and analytics, technology, legal, and human resources outsourcing services. In addition, the company offers transformation services designed to help its clients to modify their business processes to enhance productivity, as well as manage changes in the business environment and leverage business knowledge to increase market competitiveness. Further, it provides claims handling and repair management services for automobile repairs through a network of third party repair centers; and a suite of accident management services, such as credit hire and credit repair. WNS (Holdings) Limited was founded in 1996 and is based in Mumbai, India.
Receive News & Ratings for Protagenic Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Protagenic Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.